Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Pauline Siew Mei Lai, Siew Siang Chua, Yah Huei Chong & Siew Pheng Chan. (2012) The effect of mandatory generic substitution on the safety of alendronate and patients’ adherence. Current Medical Research and Opinion 28:8, pages 1347-1355.
Read now
Read now
A.D. Walker & J.D. Adachi. (2011) In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada. Current Medical Research and Opinion 27:9, pages 1749-1754.
Read now
Read now
Michael Pazianas, Cyrus Cooper, F Hal Ebetino & R Graham G Russell. (2010) Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 6, pages 325-343.
Read now
Read now
Richard J. Dansereau, Debbie J. Crail & Alan C. Perkins. (2009) In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US. Current Medical Research and Opinion 25:2, pages 449-452.
Read now
Read now
Articles from other publishers (11)
Deborah T. Gold. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1695
1707
.
Wojciech P. Olszynski, Jonathan D. Adachi & K. Shawn Davison. (2014)
Differences in
In Vitro
Disintegration Time among Canadian Brand and Generic Bisphosphonates
. Journal of Osteoporosis 2014, pages 1-6.
Crossref
Crossref
Jacques P Brown, Kenneth S Davison, Wojciech P Olszynski, Karen A Beattie & Jonathan D Adachi. (2013) A critical review of brand and generic alendronate for the treatment of osteoporosis. SpringerPlus 2:1.
Crossref
Crossref
Joop P. W. van den Bergh, Marian E. Bouts, Eveline van der Veer, Robert Y. van der Velde, Marcel J. W. Janssen, Piet P. Geusens, Bjorn Winkens, Nico J. J. Oldenhof & Tineke A. C. M. van Geel. (2013) Comparing Tolerability and Efficacy of Generic versus Brand Alendronate: A Randomized Clinical Study in Postmenopausal Women with a Recent Fracture. PLoS ONE 8:10, pages e78153.
Crossref
Crossref
Caterina Musolino & Alessandro Allegra. 2013. Pathobiology of Cancer Regimen-Related Toxicities. Pathobiology of Cancer Regimen-Related Toxicities
249
282
.
Claudia Gómez Acotto, Carlos Antonelli, Damien Flynn, Dennis McDaid & Emilio J. A. Roldán. (2012) Upper Gastrointestinal Tract Transit Times of Tablet and Drinkable Solution Formulations of Alendronate: A Bioequivalence and a Quantitative, Randomized Study using Video Deglutition. Calcified Tissue International 91:5, pages 325-334.
Crossref
Crossref
J. A. Kanis, J.-Y. Reginster, J.-M. Kaufman, J.-D. Ringe, J. D. Adachi, M. Hiligsmann, R. Rizzoli & C. Cooper. (2011) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporosis International 23:1, pages 213-221.
Crossref
Crossref
Serge Cremers & Socrates Papapoulos. (2011) Pharmacology of bisphosphonates. Bone 49:1, pages 42-49.
Crossref
Crossref
Stuart H. Ralston, Tzuyung D. Kou, Bettina Wick-Urban, Michael Steinbuch & Tahir Masud. (2010) Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate. Calcified Tissue International 87:4, pages 298-304.
Crossref
Crossref
Johann D. Ringe & Gerd Möller. (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatology International 30:2, pages 213-221.
Crossref
Crossref
Guenther Lamprecht. (2009) In vitro Determination of the Release of Alendronic Acid from Alendronate Tablets of Different Brands During Deglutition. Journal of Pharmaceutical Sciences 98:10, pages 3575-3581.
Crossref
Crossref